J.P. Morgan Sticks to Their Hold Rating for Regeneron (REGN)

By Austin Angelo

J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Regeneron (REGNResearch Report) yesterday and set a price target of $375.00. The company’s shares closed last Monday at $332.60.

According to TipRanks.com, Kasimov is a 4-star analyst with an average return of 4.7% and a 45.9% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Ultragenyx Pharmaceutical, and Alexion Pharmaceuticals.

Regeneron has an analyst consensus of Moderate Buy, with a price target consensus of $362.63, a 12.1% upside from current levels. In a report issued on October 31, Cowen & Co. also assigned a Hold rating to the stock with a $349.00 price target.

See today’s analyst top recommended stocks >>

Regeneron’s market cap is currently $36.55B and has a P/E ratio of 18.49. The company has a Price to Book ratio of 3.74.

Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of REGN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.